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Summary
Paired-like homeodomain transcription factor 1 (PITX1) was
specifically up-regulated in patients with facioscapulohumeral
muscular dystrophy (FSHD) by comparing the genome-wide
mRNA expression profiles of 12 neuromuscular disorders. In
addition, it is the only known direct transcriptional target of the
double homeobox protein 4 (DUX4) of which aberrant
expression has been shown to be the cause of FSHD. To test
the hypothesis that up-regulation of PITX1 contributes to the
skeletal muscle atrophy seen in patients with FSHD, we
generated a tet-repressible muscle-specific Pitx1 transgenic
mouse model in which expression of PITX1 in skeletal muscle
can be controlled by oral administration of doxycycline. After
PITX1 was over-expressed in the skeletal muscle for 5 weeks, the
mice exhibited significant loss of body weight and muscle mass,
decreased muscle strength, and reduction of muscle fiber
diameters. Among the muscles examined, the tibialis anterior,
gastrocnemius, quadricep, bicep, tricep and deltoid showed
significant reduction of muscle mass, while the soleus, masseter

Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an
autosomal dominant myopathy. Patients with FSHD generally
show weakness of facial and shoulder girdle muscles prior to
lower limb muscles although early involvement of the lower limb
muscles were reported in rare cases (Tyler and Stephens, 1950;
Lunt and Harper, 1991; Padberg et al., 1991; Kilmer et al., 1995).
Distinct asymmetry is a common feature of FSHD and the
asymmetry can be present in the muscles of the face, shoulder
girdle, and extremities (Lunt and Harper, 1991; Padberg et al.,
1991; Tawil et al., 1998). Of the many forms of muscular
dystrophy that exist, these particular clinical features are
relatively unique to the FSHD. Many patients have additional
symptoms such as severe inflammation of muscles, subclinical
hearing loss, and peripheral retinal capillary abnormalities
(Taylor et al., 1982; Voit et al., 1986; Arahata et al., 1995;
Padberg et al., 1995b; Padberg et al., 1995a).
Genetic studies of FSHD have shown that the disease is
associated with a deletion of D4Z4 repeats in the 4q35
subtelomeric region. In non-FSHD individuals, this region

and diaphragm muscles were not affected. The most prominent
pathological change was the development of atrophic muscle
fibers with mild necrosis and inflammatory infiltration. The
affected myofibers stained heavily with NADH-TR with the
strongest staining in angular-shaped atrophic fibers. Some of the
atrophic fibers were also positive for embryonic myosin heavy
chain using immunohistochemistry. Immunoblotting showed
that the p53 was up-regulated in the muscles over-expressing
PITX1. The results suggest that the up-regulation of PITX1
followed by activation of p53-dependent pathways may play a
major role in the muscle atrophy developed in the mouse model.
 2012. Published by The Company of Biologists Ltd. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial Share Alike
License (http://creativecommons.org/licenses/by-nc-sa/3.0).
Key words: D4Z4, Grip strength, Rotarod, Tet-off, Cell death

contains from 11 to 100 D4Z4 units while patients with FSHD
only have one to ten D4Z4 repeats (van Deutekom et al., 1993).
Several molecular models have been proposed to explain how
this deletion results in the FSHD pathology (Gabellini et al.,
2002; Jiang et al., 2003; van Overveld et al., 2003; Masny et al.,
2004; Wegel and Shaw, 2005; Dixit et al., 2007; Zeng et al.,
2009). Most of these models suggest that the loss of D4Z4 repeats
leads to the epigenetic de-repression of one or more genes in or
near the D4Z4 array. Indeed, the deletion of D4Z4 repeats in
patients with FSHD were shown to cause the remaining D4Z4
sequences to be hypomethylated (van Overveld et al., 2003). This
hypomethylation of the D4Z4 array was also observed in a very
small population of patients with FSHD, who did not have the
D4Z4 deletion (van Overveld et al., 2003). This finding suggested
that activation of a gene or genes in the D4Z4 region causes
FSHD. Several potential candidate genes have been proposed,
including double homeobox protein 4 (DUX4), FSHD region
gene 1 (FRG1), FSHD region gene 2 (FRG2), and adenine
nucleotide translocase 1 (ANT1) (Gabellini et al., 2006; Dixit et
al., 2007). A recent study conducted by Lemmers et al. suggested

Biology Open

PITX1 and muscle dystrophy
that aberrant expression of DUX4 is the cause of FSHD and ruled
out the possible involvement of the other candidate genes
(Lemmers et al., 2010).
Each D4Z4 repeat contains an ORF for DUX4, which was
initially thought to be ‘‘junk’’ DNA due to the lack of introns and
a polyadenylation signal (Gabriëls et al., 1999). The DUX4 gene
reemerged as a plausible candidate gene when studies showed
that it was evolutionarily conserved and could produce a
polyadenylated mRNA from the ORF in the last D4Z4 repeat
(Clapp et al., 2007; Dixit et al., 2007; Kowaljow et al., 2007;
Lemmers et al., 2010). In addition, the DUX4 protein was shown
to be up-regulated in the muscles of patients with FSHD, which
can transcriptionally activate paired-like homeodomain
transcription factor 1 (PITX1) (Dixit et al., 2007). In the same
study, it was proposed that the DUX4 gene in the most distal
D4Z4 element was the only copy that could be transcribed into a
polyadenylated mRNA. The polyadenylation will stabilize the
transcript to produce a functional DUX4 protein which has been
shown to be toxic to muscle cells (Kowaljow et al., 2007;
Bosnakovski et al., 2009). This hypothesis was supported by the
recent genetic study which showed that stable DUX4 mRNA is
essential to FSHD pathogenesis (Lemmers et al., 2010).
Individuals carrying contracted D4Z4 allele without a
functional polyadenylation signal of the DUX4 gene do not
have the disease.
The PITX1 gene is the only known direct transcriptional target
of DUX4, and the up-regulation of PITX1 was shown to be
FSHD-specific when comparing the genome-wide mRNA
profiles of FSHD to those of 11 other neuromuscular diseases
(Dixit et al., 2007). The PITX1 is a homeobox transcription factor
which was first recognized for its critical role in the development
and postnatal function of the pituitary gland (Lamonerie et al.,
1996; Tremblay et al., 1998). The gene was then reported playing
important roles in hindlimb development, immune modulation
and tumor suppression (Lanctôt et al., 1999; Logan and Tabin,
1999; Szeto et al., 1999; Civas et al., 2002; Kolfschoten et al.,
2005; Liu and Lobie, 2007; Calvisi et al., 2011). During
embryonic limb development, PITX1 only expresses in the
hindlimb but not the forelimb, and determines the identity of the
hindlimb (Lanctôt et al., 1999; Logan and Tabin, 1999; Szeto et
al., 1999; Marcil et al., 2003). The fetuses of Pitx1 knockout mice
exhibit remarkable structural changes in their hindlimbs, such
that they more resemble the forelimbs (Marcil et al., 2003). These
altered limbs also exhibit left-right asymmetry in the degree of
change. Chicken wing buds with mis-expressed PITX1 developed
into limbs with some of the morphological characteristics of
hindlimbs (Logan and Tabin, 1999). Interestingly, a
polymorphism in the regulatory promoter region of Pitx1 which
reduces PITX1 expression is associated with asymmetric pelvic
reduction in stickleback fish (Shapiro et al., 2004). Moreover, a
mutation that abolishes the expression of PITX1 caused
asymmetric lower-limb malformations in humans (Gurnett et
al., 2008). Although PITX1 has been reported down regulated in
cancer cells (Subramanian et al., 2004; Kolfschoten et al., 2005;
Chen et al., 2007), no known disease is caused by up-regulation
of PITX1 in human.
To date the function of PITX1 in postnatal muscles is not clear.
We know that some homeobox proteins that play critical roles
during embryonic development can also play a role in
maintaining postnatal tissue identity (Leucht et al., 2008; Rinn
et al., 2008). Based on this knowledge, we hypothesized that the
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over-expression of PITX1 in postnatal muscles may alter the
homeostasis of their gene regulatory networks, which may play a
key role in the pathogenesis of FSHD. The muscles of the
forelimbs are likely to be more susceptible to the higher
expression of PITX1 since they do not express PITX1 at high
level by default. In this study, we focused our effort on the roles
of PITX1 in postnatal skeletal muscles and generated a tetrepressible muscle-specific Pitx1 transgenic mouse model which
over-expresses the PITX1 in skeletal muscles, and is controlled
by oral administration of doxycycline. Using this model, we can
avoid over-expressing PITX1 during embryonic development, as
well as study the cell autonomous effect of PITX1 in skeletal
muscles.
Results
To generate the tet-repressible muscle-specific Pitx1 transgenic
mice (TRE-Pitx1/mCK-tTA), two transgenic mouse lines (TREPitx1 and mCK-tTA) were cross-bred. The TRE-Pitx1 line carries
a construct containing the Pitx1 gene, driven by a tretracycline
response element (TRE). The mCK-tTA line carries a construct
containing the tTA gene, driven by a muscle specific creatine
kinase promoter (mCK) as previously reported (Ghersa et al.,
1998). This tet-repressible Pitx1 transgenic mouse model allowed
us to control the timing and location of PITX1 over-expression.
The Pitx1 transgenic mice over-express the PITX1 protein in
skeletal muscle when oral doxycycline is not provided in the
drinking water. The tissue specificity of the system was verified
by assessing PITX1 expression in the skeletal muscles and organs
of adult Pitx1 transgenic mice that had been taken off
doxycycline for five weeks at age of 8 weeks. RT-PCR results
showed that Pitx1 was being expressed in the muscles but not in
the other organs examined (Fig. 1A). To quantify protein
expression level of PITX1 in the muscle, we conducted
immunoblotting using proteins from the triceps and quadricep
of the Pitx1 transgenic mice. The results showed that the PITX1
protein was 3.3 and 2.9 fold higher in the triceps and quadriceps
than in those of the control mice, respectively (Fig. 1B,C).
The Pitx1 transgenic mice developed muscle wasting
and weakness

Oral doxycycline was discontinued to induce Pitx1 expression
when the Pitx1 transgenic (TRE-Pitx1/mCK-tTA) mice were 10
weeks old. The body weight was measured weekly. The Pitx1
transgenic mice showed significant body weight loss (9%,
p,0.05) compared to control mice after five weeks of PITX1
over-expression, primarily due to the loss of muscle mass
(Fig. 2A). The musculature of the Pitx1 transgenic mice was
visibly reduced compared to control mice in most of the muscle
groups observed (Fig. 2B). After being off doxycycline for nine
to ten weeks, the mice were euthanized and masseter, soleus,
tibialis anterior, quadricep, gastrocnemius, deltoid, tricep, and
bicep muscles from both the left and right limbs, and the
diaphragm muscles were individually dissected and weighed.
Except the soleus, masseter and diaphragm, the rest of the
muscles were significantly reduced in mass compared to the
muscles from the control mice. For those muscles that lost muscle
mass after PITX1 over-expression, the muscles of the left and
right limbs were both affected significantly, except for the left
biceps of the Pitx1 transgenic mice, which did not show
significant loss (Fig. 3).

PITX1 and muscle dystrophy
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To determine whether muscle strength and coordination were
affected by PITX1 over-expression, we performed grip strength
and rotarod tests to evaluate muscle function. In comparison to
single transgenic control littermates the Pitx1 transgenic mice
showed no difference in grip strength or rotarod tests while still
receiving oral doxycycline to suppress the Pitx1 transgene
expression. The oral doxycycline was then stopped to induce
the Pitx1 transgene expression, and the mice were tested again
after three weeks. The Pitx1 transgenic mice exhibited significant
muscle weakness measured by grip strength (Fig. 4A). Although
the Pitx1 transgenic mice tended to fall off the rotarod cylinders
sooner than the control mice (Fig. 4B), the difference between
the groups was not statistically significant.
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PITX1 over-expression leads to myofiber atrophy and
muscular dystrophy

Fig. 1. Muscle-specific PITX1 over-expression in the Pitx1 transgenic mice.
(A) Detection of Pitx1 mRNA expression in muscles of the Pitx1 transgenic
mice after PITX1 over-expression was induced for five weeks. Pitx1 transcripts
were detected in the two muscles, gastrocnemius and quadricep, examined
(lanes 1 and 2), but not in the brain, heart, lung, liver, kidney or testis (lanes
3–8). Lane 9 is a negative control using RNA of quadricep without reverse
transcriptase. (B) The expression levels of PITX1 protein in the triceps and
quadriceps of the Pitx1 transgenic mice and control mice (mCK-tTA) after
PITX1 over-expression was induced for five weeks. ‘‘*’’ indicates p,0.05.
(C) Immunoblotting images of PITX1 and GAPDH. DT, Pitx1 transgenic mice;
C, control mice. B and C showed PITX1 protein was 3.3 and 2.9 fold higher in
the triceps and quadriceps than in those of the control mice, respectively.

To examine the pathological changes caused by PITX1 overexpression, we performed hemotoxylin and eosin (H&E) staining
to visualize the pathological changes in the myofibers. The most
prominent pathological change was the angular-shaped atrophic
muscle fibers in the muscle, which were not seen in the control
mice. We also observed a small numbers of necrotic and centrally
nucleated fibers with inflammatory infiltration, which indicates a
mild degeneration/regeneration process likely in response to the
muscle loss due to myofiber atrophy. Angular-shaped atrophic
myofibers that strongly stained with NADH-TR have been
reported in patients with FSHD (Fenichel et al., 1967; Hudgson et
al., 1972; Voit et al., 1986; Kissel, 1999), therefore we performed
the NADH-TR staining to determine whether similar staining
patterns could be seen in the mouse model. NADH-TR staining
showed that the myofibers of the Pitx1 transgenic mice were
heavily stained in general, while the angular-shaped atrophic
fibers stained the darkest (Fig. 5). The myofibers with central

Fig. 2. The Pitx1 transgenic mice developed muscle wasting after PITX1 over-expression was induced for 5 weeks. (A) The average body weight
(g, mean 6 s.e.) of the Pitx1 transgenic was significantly reduced compared to the control mice. The asterisks indicate significant differences with p,0.05.
(B) Skeletal muscles wasting in the Pitx1 transgenic (TRE-Pitx1/mCK-tTA) can be seen in both forelimb and hindlimb muscles.

PITX1 and muscle dystrophy
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Fig. 3. The average weight (g, mean 6 s.e.) of individual muscles of Pitx1 transgenic and control mice after PITX1 over-expression for 9 weeks. The asterisks
indicate significant differences with p,0.05.

Fig. 4. Loss of muscle strength in TRE-Pitx1/mCK-tTA mice.
Muscle functional tests showed reduced grip strength
(A) 3 weeks after PITX1 over-expression was induced. While the
Pitx1 transgenic mice tend to fall more often, the rota rod (B) test
did not show significant difference between the Pitx1 transgenic
mice and the control mice. The asterisks indicate significant
differences with p,0.05.

Fig. 5. NADH-TR positive angular-shaped myofibers was the
most prominent pathological change observed in muscles of
the Pitx1 transgenic mice (TRE-Pitx1/mCK-tTA). H&E staining
showed angular-shaped myofibers in both quadriceps and triceps,
respectively (A,E). (B,F) H&E staining of control samples. Few
of the fibers contained central nuclei suggesting the fibers were
undergoing regeneration (A). NADH-TR staining showed the
angular-shaped atrophic fibers were heavily stained (C,G) while
the fibers with central nuclei stain lightly (C). (D,H) NADH-TR
staining of control samples. Arrows indicate angular atrophic
myofibers and asterisks indicate myofibers with central nuclei.
Scale bar: 100 mm.

PITX1 and muscle dystrophy
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nuclei were not stained heavily with NADH-TR. Embryonic
myosin heavy chain is usually expressed in small regenerating
myofibers during muscle regeneration (Matecki et al., 2004). To
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determine whether the central nucleated myofibers were
regenerating myofibers, we performed immunohistochemistry
to detect embryonic myosin heavy chain in the muscles. The
embryonic myosin heavy chain was detected in the cytoplasm of
many myofibers which appeared to be atrophic instead of
regenerating (Fig. 6). The serial sections in Fig. 6 showed the
nuclei of most of the myofibers positive with embryonic myosin
heavy chain located peripheral (myonuclei were visualized by
PITX1 staining). The nuclei of few myofibers (lower arrow in B)
slightly shifted away from the peripheral although they were not
centrally localized. While some centrally nucleated fibers were
positive of embryonic myosin heavy chain, others were not
positive of it, suggesting not all centrally nucleated fibers are
regenerating myofibers.
To quantify the myofiber atrophy observed in the muscles of
the Pitx1 transgenic mice, we measured muscle fiber diameter
using minimal Feret’s diameter measurement, performed on cross
sections stained for laminin (Briguet et al., 2004). We then
ranked the myofibers based on their size, and plotted size against
rank for each myofibers in order to assess the fiber size
distribution using Kolmogorov-Smirnov test. There were
significant differences in fiber size distribution between the
Pitx1 transgenic and control mice (Fig. 7A,B). The average fiber
diameter size in the Pitx1 transgenic mice was reduced by 45%
(p,0.05) in the triceps and by 41% (p,0.05) in the quadriceps
(Fig. 7C).
PITX1 provides a potential link between the DUX4 and
p53 activation

Fig. 6. Embryonic myosin heavy chain was expressed in non-regenerating
myofibers of the Pitx1 transgenic mice (TRE-Pitx1/mCK-tTA).
(A) Cytoplasmic staining of the embryonic myosin heavy chain (brown) of
quadriceps of the Pitx1 transgenic mice. (B) Nuclear staining of PITX1 (brown)
in quadriceps of the Pitx1 transgenic mice. No staining of embryonic myosin
heavy chain (C) and PITX1 (D) was seen in control mice. Arrows indicate
angular atrophic myofibers. Scale bar: 100 mm.

The p53 tumor suppressor is a potent inducer of apoptotic cell
death and p53-dependent autophagy, which was reported to be
involved in modulating skeletal muscle growth (Soddu et al.,
1996; Tamir and Bengal, 1998; Porrello et al., 2000). Recent
studies suggested that it plays a critical role in the DUX4 induced
myopathy (Wallace et al., 2011; Vanderplanck et al., 2011). To

Fig. 7. Minimal Feret’s diameter measurement showed the myofibers of the Pitx1 transgenic mice (TRE-Pitx1/mCK-tTA) is significantly smaller compared
to the control samples. The normalized rank was plotted against myofiber diameters of triceps (A) and quadriceps (B). Muscles of the Pitx1 transgenic mice (DT1–
DT4) were plotted in gray while those of control mice (C1–C4) were plotted in black. (C) A graphic presentation of the means of myofiber diameter. ‘‘*’’: p,0.05.

PITX1 and muscle dystrophy
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Fig. 8. p53 up-regulation in TRE-Pitx1/mCK-tTA mice. The tumor
suppressor protein p53 was up-regulated in the Pitx1 transgenic mice after overexpressing PITX1 for 5 weeks (A). ‘‘*’’: p,0.05. Immunoblotting images of
p53 and GAPDH (B). DT, Pitx1 transgenic mice; C, control.

determine the expression level of p53 in muscles of the Pitx1
transgenic mice, we performed immunoblotting and found that
p53 was 1.7 (p,0.05), and 1.9 (p,0.05) fold up-regulated in the
triceps and quadriceps of the Pitx1 transgenic mice, respectively
(Fig. 8).
We previously reported that PITX1 was specifically upregulated in patients with FSHD. In addition, DUX4 interacts
with the PITX1 promoter and activates the PITX1 expression by
luciferase and electrophoretic mobility shift assays (Dixit et al.,
2007). In this study, we further showed that DUX4 directly binds
to the PITX1 promoter using the ChIP assay (Fig. 9A).
Quantitative PCR data showed that PITX1 promoter was
enriched 8.4-fold in comparison to negative control. The
enrichment was not seen in the GFP transfected samples
(Fig. 9B). The data generated in the study provided evidence of
a regulatory cascade from DUX4 to PITX1 followed by p53
induction.
Discussion
Due to the lack of an ortholog of DUX4 in the mouse genome,
the attempt to generate and study a Dux4 transgenic mouse model
has been challenging (Bosnakovski et al., 2009). Therefore,
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generating animal models to study genes or pathways directly
regulated by DUX4 becomes a valuable alternative approach for
understanding the disease mechanisms. In this study, our results
showed that the Pitx1 transgenic mice developed phenotypes
similar to those of patients with FSHD, including the wasting of
selective groups of muscles and the NADH-TR positive atrophic
myofibers often seen in FSHD biopsies (Fenichel et al., 1967;
Hudgson et al., 1972; Slipetz et al., 1991; Kissel, 1999). We
further showed that the p53 pathway, which was recently
reported to be involved in DUX4 induced myopathy in vivo,
was up-regulated by PITX1 over-expression. The findings in this
study provide links between aberrant DUX4 expression, upregulation of PITX1, the activation of the p53-dependent cell
death pathways, and the down-stream muscular dystrophy
phenotype.
In addition to the myofiber atrophy that occurs in some
inherited muscle diseases (Emery, 2002), skeletal muscle atrophy
occurs when the muscle is disused, immobilized, denerved and
during starvation (Andersen et al., 1999; Jagoe et al., 2002;
Jackman and Kandarian, 2004). Muscle atrophy also occurs
under other disease conditions such as cancer cachexia, kidney
disease, and mitochondrial diseases (Tisdale, 1997; Qureshi et al.,
1998; Weissman et al., 2008). Many molecular pathways have
been reported to be involved in the muscle atrophy process
(Bodine et al., 2001b; Bodine et al., 2001a; Pallafacchina et al.,
2002; Mammucari et al., 2007). Among the known pathways,
several studies showed that p53 plays critical roles in myogenesis
and muscle wasting (Soddu et al., 1996; Tamir and Bengal, 1998;
Porrello et al., 2000). The p53 protein was shown to be activated
during myoblast differentiation. Through a protein-protein
interaction with MyoD, it transcriptionally activates muscle
creatin kinase (MCK), a late muscle differentiation marker
(Tamir and Bengal, 1998). Several studies showed that p53 is
required for TNF-mediated inhibition of muscle differentiation as
well as the tumor-load mediated muscle atrophy (Coletti et al.,
2002; Schwarzkopf et al., 2006; Moresi et al., 2008). A mouse
model with a stable and chronically activated p53 protein
develops muscle atrophy at 18–24 months of age, although the
mice are more resistant to cancer (Tyner et al., 2002). In healthy
tissues and cells, the p53 protein level is low with cytoplasmic
localization. Upon activation in response to stress signals (such as
DNA damage, UV radiation and hypoxia) p53 translocates to the
cell nuclei and activates downstream genes and pathways
involved in cell survival and apoptosis (Aranda-Anzaldo et al.,
1999; Vousden, 2000). It has been shown that over-expression of
DUX4 in murine C2C12 and human rhabdomyosarcoma cells

Fig. 9. Chromatin immunoprecipitation demonstrates DUX4 binding of the PITX1 promoter. (A) Diagram of the mouse and human PITX1 promoters, which
share high identity for non-coding DNA regions. The grey box indicates the position of the conserved DUX4 binding site, which sits immediately adjacent to the
PITX1 promoter ChIP amplicon (black box). (B) Representative PCR amplification of the PITX1 promoter following DUX4 ChIP (from 3 independent experiments).
The amplicon of PITX1 promoter was enriched 8.4-fold following DUX4 ChIP whereas negative control blank and GFP showed no enrichment in comparison to the
beads control. L, 100 bp ladder.
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induce cell death through apoptosis (Kowaljow et al., 2007). The
toxic effect of DUX4 over-expression was recently confirmed in
vivo. In that study, the p53-dependent cell death pathway was
identified to be the cause of the DUX4 induced myopathy,
although the mechanistic link between DUX4 and p53 was not
clear (Wallace et al., 2011). In this study, we showed that overexpression of PITX1 up-regulated p53 expression, which
provides a potential link between DUX4 and p53 activation in
muscles.
Down-regulation of PITX1 expression has been observed in
several cancers including lung, colon, prostate and bladder
cancers (Singh et al., 2002; Subramanian et al., 2004;
Kolfschoten et al., 2005; Chen et al., 2007). In addition to its
role in muscle development, recent studies showed that PITX1
also acts as a tumor suppressor. Up-regulation of PITX1 induces
apoptosis in cancer cells through the activation of the p53dependent cell death pathway (Liu and Lobie, 2007; Yamaguchi
et al., 2010; Calvisi et al., 2011). In addition, PITX1 suppresses
telomerase reverse transcriptase (TERT) transcription through
direct binding to the TERT promoter, which reduces the
telomerase activity that maintains telomere length in cancer
cells (Qi et al., 2011). In the p53-dependent pathway, PITX1 was
shown to bind directly to the regulatory elements of the p53
promoter, and activates p53 transcription with subsequent
apoptosis in human mammary carcinoma cells (Liu and Lobie,
2007). Recently, p53 and its regulatory targets were reported to
be up-regulated in FSHD (Tsumagari et al., 2011; Vanderplanck
et al., 2011). In addition, treatment with antisense
oligonucleotides targeting DUX4 reduced the expression of p53
in patients’ myoblasts. Although not directly examined, several
studies suggested that apoptosis is likely to be involved in the
pathogenesis of FSHD. For example, genes involved in apoptosis
such as BCL2-associated X protein (BAX), B-cell lymphoma 2
(BCL2) and Caspase-3, Caspase-2, Caspase-6, Caspase-8, and
Granzyme-B, have been reported to be up-regulated in the
muscles of patients with FSHD (Sandri et al., 2001; Winokur et
al., 2003; Laoudj-Chenivesse et al., 2005). Our findings support
that the p53-depedent cell death pathways might be involved in
FSHD pathogenesis, and needs to be further studied.
In our study, the decrease in muscle mass of the Pitx1
transgenic mice is primarily due to muscle atrophy, which was
observed soon after inducing PITX1 over-expression.
Histological examination showed dystrophic features including
large number of atrophic myofibers, mild cellular infiltration, and
some necrotic and central nucleated fibers. Myofiber necrosis,
regeneration, inflammatory infiltration, and fibrosis are common
pathologies seen in several muscular dystrophies, including
FSHD (Taylor et al., 1982; Lin and Nonaka, 1991; Arahata et al.,
1995; Neudecker et al., 2004; Reilich et al., 2010). In addition to
these pathological changes, muscle atrophy with marked numbers
of angular-shaped atrophic fibers was also observed in FSHD
muscle (Fenichel et al., 1967; Furukawa et al., 1969; Voit et al.,
1986; Lin and Nonaka, 1991; Arahata et al., 1995; Kissel, 1999).
While myofiber atrophy due to denervation/renervation generally
involves ‘‘grouped’’ angular-shape atrophic fibers, atrophic
myofibers with a myogenic cause tend to be scattered (Banker,
1986; Benedetti et al., 2005). The angular myofibers in FSHD
were proposed to be due to a myogenic cause due to their
scattered distribution (Engel and Kossman, 1963; Lin and
Nonaka, 1991; Nakagawa et al., 1997). We observed the same
scattered distribution of angular-shaped myofibers in the Pitx1
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transgenic mice muscles. In addition, angular-shaped atrophic
fibers that strongly stain with NADH-TR and myofibers that are
positive for embryonic myosin heavy chain are found in both
patients with FSHD and our Pitx1 transgenic mice (Fenichel et
al., 1967; Hudgson et al., 1972; Voit et al., 1986; Kissel, 1999).
Regenerating myofibers that are positive for embryonic
myosin heavy chain are seen in muscular dystrophies and
mouse models of those diseases (Chen et al., 2000; Matecki et al.,
2004). These regenerating fibers are usually small in size,
clustered in groups and centrally nucleated. Here we show that
the myofibers undergoing muscle atrophy can also express
embryonic myosin heavy chain. Most of the fibers positive for
embryonic myosin heavy chain in the Pitx1 transgenic mice do
not show characteristics of regenerating myofibers. Instead they
show feature of atrophic fibers. We hypothesize that the
expression of the embryonic myosin heavy chain in the
affected fibers is part of a compensatory response to the
ongoing muscle atrophy process.
During embryonic development, the expression of PITX1 was
observed high in hindlimb but not in the forelimb, which plays a
critical role to hindlimb identify (Lanctôt et al., 1999; Logan and
Tabin, 1999; Szeto et al., 1999). Interestingly PITX1 has been
shown to have a left-right asymmetric effect when the expression
level of the gene was reduced or eliminated (Lanctôt et al., 1999;
Marcil et al., 2003; Shapiro et al., 2004). Since the facial and
certain muscles in the shoulder girdle are the most affected in
patients with FSHD, and the weakness can often be asymmetric,
it would be important to determine whether a similar pattern of
muscle involvement can be seen in our mouse model. It is known
that specific groups of muscles (ex. facila, pectoralis major,
zygomaticus, orbicularis oris, triceps, biceps and trapezius
muscles) of patients with FSHD are affected earlier, while
some are affected later (tibialis, foot extensor, gastrocnemius,
quadricep and abdominal muscles) (Tyler and Stephens, 1950;
Lunt and Harper, 1991; Olsen et al., 2006; Castellano et al., 2008;
Reilich et al., 2010) or generally spared (ex. deltoid, bulbar,
masseter, gluteal, peroneal extraocular, pharyngeal, lingual and
cardiac muscles) (Padberg et al., 1991; Tawil et al., 1998; Olsen
et al., 2006; Tawil and Van Der Maarel, 2006; Reilich et al.,
2010). In addition, the muscle weakness can often to be left-right
asymmetric (Brouwer et al., 1991; Lunt and Harper, 1991; Tawil
et al., 1998). To determine whether selected muscle groups of the
Pitx1 transgenic mice are affected differentially, and whether the
muscle atrophy is left-right asymmetric, we collected and
weighed both the left and right tibialis, gastrocnemius, soleus,
quadricep, bicep, tricep, deltoid and masseter muscles of the
Pitx1 transgenic and control mice. Indeed, the masseter and
diaphragm muscles, which are usually spared in patients with
FSHD, were also not affected in the Pitx1 transgenic mice. Most
of the limb muscles except the soleus developed muscle atrophy
and lost significant muscle weight. No left-right asymmetric
involvement was observed in most of the muscles examined.
Only the biceps of the Pitx1 transgenic mice showed asymmetry.
The biceps is one of the muscles that is most affected in patients
with FSHD, and can be asymmetrically affected. Detailed
pathological examination of the muscles collected from both
sides will provide additional information for evaluating the
asymmetric involvement of the biceps.
Transcription factor PITX2 is in the same protein family as
PITX1. During early embryogenesis, PITX2 is a key regulator in
establishing embryo left-right asymmetry (Yoshioka et al., 1998).

PITX1 and muscle dystrophy
PITX2-deficient mice are embryonic lethal and show severe
defects in heart, eye, pituitary gland and tooth organogenesis
(Kioussi et al., 2002). PITX2 was shown expressed in limb
muscle precursors during embryonic development and can
transcriptionally activate MyoD in the cells (L’Honoré et al.,
2007; Shih et al., 2007; L’Honoré et al., 2010; Zacharias et al.,
2011). PITX1 and PITX2 have been shown to be either coregulated or functionally overlapped in multiple organs including
hindlimb during embryonic development (St Amand et al., 2000;
Marcil et al., 2003; Lamba et al., 2008; Castinetti et al., 2011).
Considering the critical role of PITX2 in left-right asymmetry
and limb development, it is possible that PITX2 is involved in the
pathology seen in this model. Based on unpublished microarray
data generated in our lab, we did not see expression change of the
Pitx2 transcript in the Pitx1 transgenic mice, suggesting PITX2 is
not involved in the myopathy caused by over-expressing PITX1.
In this study, we characterized a mouse model that
conditionally over-expresses PITX1 in skeletal muscles, and
showed that the mice exhibit phenotypes of muscle weakness and
myopathy. In addition, our data suggest a regulatory cascade
from DUX4, PITX1 to p53.
Materials and Methods
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Generation of the tet-repressible muscle-specific transgenic
Pitx1 mouse
All animal procedures were approved by the IACUC committee at the Children’s
National Medical Center in Washington, DC. Two transgenic mouse lines (TREPitx1 and mCK-tTA) were cross-bred in order to generate the tet-repressible
muscle-specific Pitx1 transgenic mice (TRE-Pitx1/mCK-tTA). The TRE-Pitx1 line
carries a construct containing the Pitx1 gene, driven by a tretracycline response
element (TRE). The mCK-tTA line carries a construct containing the tTA gene,
driven by a muscle specific creatine kinase promoter (mCK) as previously reported
(Ghersa et al., 1998). To generate the TRE-Pitx1 mice, the Pitx1 coding sequence
from MGC-13954 (ATCC) was subcloned into the pBI-G vector (Clontech,
Mountain View, CA, USA) by Not1 and Sal1 digestion (Invitrogen, Carlsbad, CA,
USA), followed by restriction site blunting with klenow DNA Polymerase I
(Invitrogen, Carlsbad, CA, USA). The pBI-G vector was prepared by Not1
digestion, followed by restriction site blunting with klenow DNA Polymerase I.
After being purified by Qiagen purification kit (Qiagen, Germantown, MD, USA),
the blunt ends were dephosphorylated with calf intestine phosphatase (CIP) (New
England Biolabs, Ipswich, MA, USA) at 37 ˚C for one hour. The Pitx1 and vector
fragments were ligated together via T4 DNA ligase overnight incubation at 16 ˚C.
The insertion of the Pitx1 fragment into the vector was validated by nucleotide
sequencing (Beckman Coulter, Danvers, MA, USA). The backbone of the pBI-GPitx1 vector was removed via AclI and Asel (New England Biolabs, Ipswich, MA,
USA) digestion, followed by gel purification with a GELase Agrose gel-digestion
preparation kit (Epicentre Biotechnologies, Madison, WI, USA). The purified
construct was microinjected (10 ng/ml) into the pronuclei of B6CBAF1 fertilized
0.5 day old mouse oocytes. The injected oocytes were then transferred to the
oviducts of pseudopregnant ND4 outbred foster mothers.
The founder female mouse with the TRE-Pitx1 transgene was bred with a C57Bl/
10 male to expand the line. The Pitx1 transgenic mice were generated by crossbreeding the TRE-Pitx1 and mCK-tTA mice. The female mice received drinking
water with doxycycline (200 ug/ml with 5.0% sucrose) in order to suppress the Pitx1
transgene expression in the pups in utero. Under these conditions, the TRE-Pitx1/
mCK-tTA Pitx1 transgenic mice were born at the expected Mendelian ratio. The pups
continued to receive doxycycline through the mother’s milk. After weaning, all pups
were maintained on water treated with doxycycline until they were entered into an
experimental regime. For all experiments, littermates carrying a single transgene
(Pitx1 or tTA) were used as controls.
To identify mice carrying one or two of the transgenes (Pitx1 and tTA), we
collected a small piece of tail tip and isolated DNA for genotyping. The following
primers were used for polymerase chain reaction (PCR) amplification. For Pitx1:
forward 59-TGG AGG CCA CGTTCC AAA G-39 and reverse 59- GTTCTTGAACCAGACCCGCAC-39; for tTA: forward 59-ACAGCGCATTAGAGCTGCTT-39
and reverse 59-CCCCTTCTAAAGGGCAAAAG -39.

Body and muscle mass
We removed doxycycline from the water of 9 Pitx1 transgenic (TRE-Pitx1/mCKtTA) mice and the control littermate mice (TRE-Pitx1 or mCK-tTA) at 10 weeks
old, and measured their body weight weekly, starting from the date that
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doxycycline was first removed from their water. After being off doxycycline for
nine to ten weeks, the mice were euthanized. Masseter, soleus, tibialis anterior,
quadriceps, gastrocnemius, deltoid, triceps, biceps and the diaphragm from five
Pitx1 transgenicand control mice were dissected and immediately weighed. The
data were expressed as the mean 6 s.e. Significant differences between
the induced Pitx1 transgenic mice and the controls were tested by 2-tailed
T test. The significance cutoff was p,0.05.

Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from tissues using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA), following the manufacturer protocol. Briefly, 1 mg total RNA
was first treated with DNaseI, followed by single strand cDNA synthesis using
oligo dT and Superscript II RT (Invitrogen, Carlsbad, CA, USA). Primers used for
amplifying Pitx1 transcripts are as follows: forward 59-TGG AGG CCA CGT TCC
AAA G-39 and reverse 59- GTT CTT GAA CCA GAC CCG CAC-39. The PCR
condition was 35 cycles of 94 ˚C for 45 second, 57.5 ˚C for 45 second, followed by
72 ˚C for 1 minute 30 second. The amplified product was visualized on a 2%
agarose gel (Gibco BRL, Gaithersburg, MD, USA).

Immunoblotting
Muscle sections were digested with a hand sonicator for 10 seconds at room
temperature in lysis buffer (50 mM Tris-HCL, pH 7.5, 150 mM NaCl, 0.5%
sodium deoxycholate, 1% NP40, 0.1% SDS, and protease inhibitor). Protein
concentration was determined by DC protein assay (Bio-Rad, Hercules, CA, USA),
and 30 mg of protein was loaded to 4–12% Bis-Tris NuPage Mini Gels (Invitrogen,
Carlsbad, CA, USA) then transferred to Hybond nitrocellulose membranes
(Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). After blocking,
the membrane was incubated with rabbit polyclonal anti-PITX1 antibody (1:2,000)
(Dixit et al., 2007), anti-p53 (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) followed by secondary antibodies conjugated with HRP (Amersham
Biosciences, Little Chalfont, Buckinghamshire, UK). Chemiluminescent
substrate (Pierce, Rockford, IL, USA) was used to visualize the target proteins
on blue light autorad film (BioExpress, Kaysville, UT, USA). Detection of loading
control GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was similarly
performed with 1:1000 dilution of the mouse monoclonal primary antibody. Band
density of the target protein was measured using a GS 800 Calibrated Densitometer
(Bio-Rad, Hercules, CA, USA) then normalized to the density of GAPDH.

Muscle function testing
The grip strength test (Grip Strength Meter, Columbus Instruments, Columbus,
OH, USA) and the rotarod test (Columbus Instruments, Columbus, OH, USA) were
performed on 7 Pitx1 transgenic mice and 7 control littermates. The mice were 14
weeks old when the doxycycline was removed from their drinking water. The
functional tests were performed twice: before the mice were off doxycycline and 3
weeks after the mice were off doxycycline.
The Grip Strength Meter (GSM) consists of two steel grids connected to force
meters. The forelimb grid is horizontal and the hind limb grid is angled. Grip
strength is tested by holding the mouse over the grid until the mouse can grip the
steel bars. Then the mouse is pulled away from the force meter until it releases the
grid. The meter records the maximum force that was applied. The mice were
acclimated to the GSM for five minutes, one day prior to data collection. They
were then tested once a day for five consecutive days; five measurements were
recorded for each test. The largest measurements from each of the five tests were
averaged and normalized to body weight (kg).
For the rotarod test, the mice were acclimated to the rotarod apparatus for two
consecutive days prior to data collection. During acclimation the mice were placed
on the rotarod twice a day for two minutes, at a speed of 5 rotations per minute. If
the mice fell off the cylinder before the two minutes were up, they were placed
back on the cylinder. The mice were then tested twice a day for three consecutive
days. During each test, the cylinder was set at a speed of 10 rotations per minute
for one minute. If the mice fell off the cylinder before the minute was up, they
were placed back on the cylinder. After one minute the speed accelerated at a rate
of 1.2 rotations per second until it reached 40 rotations per minute. Starting at the
beginning of the acceleration phase, the length of time (in seconds) that each
mouse could stay on the cylinder before falling off was recorded. The maximal
running time is 180 seconds. The final score was determined by averaging the
recorded time from all six trials.

Histology, NADH-TR staining, immunohistochemistry, and
fiber diameter
Eight week-old mice were off oral doxycycline for 5 weeks before muscle
collection. Immediately after dissection, the whole muscles were snap-frozen in
isopentane cooled with liquid nitrogen, then stored at 280 ˚C until sectioning. A
Leica CM 1900 cryostat (Walldorf, Baden-Wurttenberg, Germany) was used to
prepare cryosections for all the following histological analyses. H&E staining was
conducted using 8 mm sections. Five random non-overlapping fields of the tissue
section were imaged using Nikon Eclipse E800 microscope (Nikon, Chiyoda-ku,
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Tokyo, Japan), RT slider camera (Diagnostic Instrument, Sterling Height, MI,
USA) and SPOT advanced software.
For NADH-TR staining, 12 mm cryosections were prepared then incubated in
solution with NBT (Nitro-blue tetrazolium 200 mg, Tris buffer 100ml) (Sigma,
Saint Louis, MO, USA) and NADH (NADH 20mg, Tris buffer 50 ml) (Sigma,
Saint Louis, MO, USA) at 37 ˚C for 30 minutes. The sections were then washed
three times with deionzed H2O, followed by serial acetone immersions at the
following concentrations: 30%, 60%, 90%, 60%, and 30%. The sections were
washed three times with deionzed H2O before being mounted with aqueous
medium.
For immunohistochemistry, 4 mm muscle sections were fixed in cold acetone for
10 min, and then incubated with primary antibody at 4 ˚C overnight. The primary
antibodies used for PITX1 and embryonic myosin heavy chain detection is rabbit
polyclonal anti-PITX1 (1:500) (Dixit et al., 2007) and mouse monoclonal antiembryonic myosin heavy chain antibody F1.652 (Hybridoma bank, Iowa City,
Iowa, USA) (1:20), respectively. The ABC kit (Vectors Lab, Burlingame, CA,
USA) was then used to detect the primary antibody bound target proteins. The
sections were stained with nuclear dye Hoechst 33258 (1:2500 dilution) to
visualize nuclei. The muscle sections were imaged using Nikon Eclipse E800
microscope, RT slider camera and SPOT advanced software. To measure myofiber
diameter, 6 mm cryosections were prepared from the muscles of 4 Pitx1 transgenic
and 4 control littermates. The sections were fixed using cold acetone, blocked
using 10% horse serum, and then incubated with rabbit anti-laminin antibody
(Sigma, Saint Louis, MO, USA) at a dilution of 1:400. After the sections were
washed three times with PBS, we applied Cy2 donkey anti-rabbit antibody
(Jackson ImmunoResearch, West Grove, PA, USA) at a dilution of 1:500. The
images of 5 random fields were processed using Image J software (NIH) and the
minimal Feret’s diameter was measured. To obtain the actual micron size we set a
scale using a microscope scale (Graticules) where 1 pixel 55.40 mm. The fibers
were first ranked based on their size than the rank number was divided by the total
number of fibers to obtain a value between 0 to1. This number (Y-axis) is then
plotted against the fiber diameter (X-axis). The Kolmogorov-Smirnov test was
used to determine the significance of the difference in fiber size distribution (http://
www.physics.csbsju.edu/stats/KS-test.n.plot_form.html).

Chromatin immunoprecipitation (ChIP)
HEK293 cells were grown in DMEM supplemented with 10% FBS. Five million
cells were transfected with AAV.CMV.hrGFP or AAV.CMV.DUX4.V5 proviral
plasmids (Wallace et al., 2011). After 48 hrs, cells were cross-linked with 1%
formaldehyde and cross linking was stopped after 10 min using 0.125 M glycine.
Chromatin was extracted with ChIP lysis buffer (1% SDS; 10 mM EDTA, pH 8.0;
50 mM Tris-Cl, pH 8.0; 1 mM PMSF; 16 cocktail protease inhibitor) Chromatin
was sheared on ice to 300,600 bp by sonication (Sonics, Newtown, CT, USA) and
800 mg were pre-cleared with protein G-agarose beads (Invitrogen, Carlsbad, CA,
USA), followed by immunoprecipitation with 5 mg agarose conjugated-V5
antibody (Bethyl Laboratories, Montgomery, TX, USA) at 4 ˚C overnight. The
immune complexes were washed sequentially with low salt (0.1% SDS; 2 mM
EDTA, pH 8.0; 20 mM Tris-Cl, pH 8.0; 150 mM NaCl; 1% Triton X 100), high
salt (0.1% SDS; 2 mM EDTA, pH 8.0; 20 mM Tris-Cl, pH 8.0; 500 mM NaCl;
1% Triton X 100), LiCl wash buffer (2 mM EDTA, pH 8.0; 20 mM Tris-Cl,
pH 8.0; 250 mM LiCl; 1% NP-40; 1% deoxycholate) and TE buffer DNA-protein
complexes were reverse cross-linked using 5 M NaCl. DNA was purified and
resuspended in 30 ml H2O. SYBR-green real-time PCR was performed with the
following primers using 1 ml of ChIP DNA: PITXI 59-CCTAAGGTGTAAAACAAGGGGAGAG-39 (forward); 59-CGGGATTGGGATAGAAATGATGG-39
(reverse) and a 55 ˚C annealing temperature. These primers amplify a specific,
146 bp DNA fragment located 641 bp upstream of the PITX1 exon 1 and 64 bp
upstream of a DUX4 binding site located in the PITX1 promoter (Dixit et al.,
2007). In addition to real-time PCR, PITX1 amplicons were also electrophoresed
on 1.5% agarose gel and visualized by ethidium bromide staining. Data shown are
representative of three independent experiments. Input DNA controls were diluted
1:200 prior to PCR. Real-time PCR signal was normalized to a standard curve and
fold enrichment was calculated using a ‘‘signal over background method’’ as per
manufacturer’s instructions (http://www.invitrogen.com/site/us/en/home/Productsand-Services/Applications/epigenetics-noncoding-rna-research/ChromatinRemodeling/Chromatin-Immunoprecipitation-ChIP/chip-analysis.html). Reported
values represent the ratio of PITX1 signal in ChIP samples over beads (without
antibody) control samples.
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